Dispute flares inside FDA over safety of popular blood drugs

Within the FDA, blood apparently is not thicker than water. An unusually public tiff has arisen over the use of angiotensin receptor blockers, or ARBs, which millions of Americans use to prevent heart attack, stroke and heart failure. Some dissenting doctors within the FDA feel that not enough research has gone into monitoring some of the unintended consequences of the drugs, namely, high cancer rates.